Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Seminar burkholderia 1

4,686 views

Published on

Burkholderia

Published in: Health & Medicine
  • Be the first to comment

Seminar burkholderia 1

  1. 1. Burkholderia Dr Sandhya Kulkarni
  2. 2. OUTLINE • Introduction • History & Diversity and taxonomy • Epidemiology – Agent • Morphology and cultural characteristics • Virulence factors and pathogenesis, immunopathogenesis – Environment – Host • Risk factors • Clinical syndromes • Laboratory diagnosis • Management and Prevention
  3. 3. INTRODUCTION
  4. 4. Introduction • Complex group of organisms exhibiting extreme diversity in • Genus contains over 40 species • Host specificity • Biochemical and physiologic activity • Nonfermenting gram negative bacteria - NFGNB – ? Emerging bacterial pathogens / often missed either as contaminants or reported as Pseudomonas species across the world • Burkholderia pseudomallei • Burkholderia mallei • Burkholderia cepacia complex – BCC – HETEROGENOUS GROUP OF nine genomovars • Burkholderia gladioli • Key microbial constituents of rhizosphere – Role in environment
  5. 5. Emerging pathogens • Burkholderia pseudomallei – Causative microbe of Meliodosis / Whitmore's disease – Recent recognition southeast Asia, Australia – Possibly under-diagnosed in India • Burkholderia cepacia complex – BCC – Increasingly common nosocomial pathogen & recent reports of community aquired infections • high intrinsic and acquired antimicrobial resistance, lack of effective antibiotics, and survival ability in the environment for prolonged periods of time
  6. 6. Burkholderia - Role in Rhizosphere – Gulf between agricultural and medical sciences • Fixation of atmospheric nitrogen • Inhibition of plant pathogens including fungi • Degradation of complex compounds like phosphates • Used in agriculture – for economical reason – Biocontrol – Bioremediation – Plant growth promotion
  7. 7. Role in Rhizosphere – one example of experiments • Qualitative phosphatase assay using 0.1% phenolphthalein phosphate agar. Seedlings non-inoculated (a) and inoculated (b) with Burkholderia spp • Infected seeds showed significant increases – in plant height, – plant biomass and – root length
  8. 8. History & Diversity and taxonomy Interest arose as MELIODOSIS emerged
  9. 9. History • 1882 – Loeffler & Schultz Glanders ..isolation of Bacillus mallei • 1912 – Alfred Whitmore & Krishnaswamy Glanders-like: in morphia addicts ..Rangoon • 1932 – Stanton & Fletcher .. Bacillus whitmorii Greek - Melis: distemper of asses, eidos: resemblance • 1970 – Public health importance – thailand and other SE Asia countries, Northern Australia Fatal CAP , 20 % in Thailand » Bacillus pseudomallei,, Malleomyces pseudomallei, Pseudomonas pseudomallei – Vietnam Time Bomb – In Returning soldiers • 1973 – Pellaroni work – Pseudomonas Genus Dissection into 5 clusters • 1970 - 80’ s – Cepacia syndrome – Isolation of these species (now under BCC) from Cystic fibrosis patients - Selective agars • 1992 – Yabuuchi et al – Cluster II dissected further Genus Burkholder .. – named after Walter Burkholder
  10. 10. Walter Hagemeyer Burkholder, 1891–1983 Phytopathologist • Ph.D. degree from Cornell University • Pioneer in bacterial taxonomy - major genera of plant-pathogenic bacteria that had been lumped into the genus Phytomonas. • Burkholder’s classification scheme - Bergey’s Manual of Determinative Bacteriology - served as editor of the phytopathogenic bacteria section for many years. • First described Pseudomonas cepacia (Burkholderia cepacia) in 1949 as a cause of rot on onion bulbs. The genus Burkholderia is named in his honor. REVIEW ARTICLE Burkholderia cepacia: medical, taxonomic and ecological issues J. R. W. GOVAN - J. Med. Microbiol. - Vol. 45 (1996), 395407 http://www.apsnet.org/about/history/pioneeringplantpathologists/Pages/BurkholderWalterHagemeyer.aspx
  11. 11. History - Taxonomy • Burkholderia cepacia complex - BCC – a clinical laboratory differentiation of species within the Bcc is lacking – Phenotypically similar but genotypically distinct groups – 1997 Vandamme et al, 2001 Coenye et al - Nine genomovars – Novel genomovars - expanding knolwedge – Genomovars - By recA gene amplification Why we need to know? Cause of concern for in India .. Antimicrobial resistance, person-to-person transmission and hospital outbreaks I. B. cepacia II. B. multivorans III. B. cenocepacia IV. B. stabilis V. B. vietnamiensis VI. B. dolosa VII. B. ambifaria VIII. B. anthina IX. B. pyrrocinia MOST common in cystic fibrosis / outbreaks In UK and USA B. cenocepacia BCC – III B. multivorans BCC - II
  12. 12. Epidemiology - Agents
  13. 13. MICROBIOLOGY BCC B. Pseudomallei B. Mallei Morphology Slender, multitrichous flagella 2-4 polar flagella, vacuolated, slender, rounded ends. Short oval/long parallel filaments, depending upon colony morphotype Straight, slightly curved 2-5 m long and 0.3- 0.8m wide; rounded ends, irregularly parallel/wavy sides, arranged in singles/in pairs/palisade/ chinese letter;no flagella/ capsule Staining Irregular Irregular; Bipolar, safety pin; particularly in pus films. Sudan Black for poly beta hydroxybutyrate Irregular, granular inclusions ISOLATION On NA/BA/MA On NA/BA/MA On NA, BA; NOT ON MA Incubation optimum temp&time 25-35 deg C for 48 hours 37 deg C, 24 - 48 hours Colony NA -Opaque, Greyish white / reddish purple PIGMENT & NLF ON MA Smooth/rough with dull wrinkled, corrugated / honeycombed surface; cream/tan; a/b lysis on BA; Earthy/Musty odor*safety NA – smooth, grey, translucent; Growth at 41 deg C Present Present, and at 42 deg C Absent Selective media Sputum samples OF agar with lactose, PolymixinB, Bacitracin; Malka broth enrichment Ashdown’s medium – eg. sputum Modified Ashdown’s- with Nile blue Gallimand’s medium – from soil Media with bacitracin & crystal violet to inhibit Gram Positive Bacteria Alert signs Patient history of CF/CGD Recurrence/chronicity Patient history, bipolar stain, Resistant to Aminoglycosides & Colistin; Sensitive to Amoxyclav Laboratory should be informed if diagnosis is suspected AST guidelines CLSI available disc diffusion –cefta, cotri, mero, mino ONLY MIC for ticar+clav, LEVO, chloram M-45 M-45?
  14. 14. Most common colony morphology of B. pseudomallei on Ashdown’s agar - The colony appears irregular-edge, rough and pale purple.
  15. 15. B. pseudomallei isolates exhibit a variety of colony morphologies. O'Connell H A et al. Appl. Environ. Microbiol. 2009;75:5405-5409
  16. 16. Biological Relevance of Colony Morphology and Phenotypic Switching by Burkholderia pseudomallei J. Bacteriol. February 2007 vol. 189 no. 3 807-817 • Morphotypes were divided into seven types (denoted I to VII). • Type I gave rise to other morphotypes (most commonly type II or III) by a process of switching in response to environmental stress, including starvation, iron limitation, and growth at 42°C. • Switching was associated with complex shifts in phenotype, one of which (type I to type II) was associated with a marked increase in production of factors putatively associated with in vivo concealment. • Mixed B. pseudomallei morphologies were common in individual clinical specimens and were significantly more frequent in samples of – blood, pus, and respiratory secretions than in urine and surface swabs.
  17. 17. Seven unique B. pseudomallei colony morphotypes on Ashdown's agar. Chantratita N et al. J. Bacteriol. 2007;189:807-817
  18. 18. Burkholderia cepacia BCSA OFPBL
  19. 19. BCC
  20. 20. Microscopy Burkholderia pseudomallei
  21. 21. Recommended simple screening Gentamicin & Colistin Resistant; Amoxyclav susceptible = NFGNB Subcultured on Ashdown’s medium for 48-72 hours
  22. 22. Biochemical BCC Gladioli B. Pseudomallei B. Mallei Motility + + + Nonmotile Oxidase +/v V + + Growth MA + + + + Lysine + - - - Arginine - NA + + Ornithine + - - - Maltose + - + + Lactose + - + +
  23. 23. Pseudomonas Burkholderia Ralstonia Pandoraea Acidovorax B. gladioli Acinetobacter Stenotrophomonas Pseudo spp luteola, oryzhihabitans Resistant to POLYMIXIN B 300 mg Burkholderia (BCC, pseudomallei, mallei) Ralstonia (should be urease positive) Moller’s ARGININE positive and motile Burkholderia pseudomallei Gram’s stain, colony morphology and AST pattern important clues to aid in identification P. stutzeri is Arginine negative L – Arabinose Assimilation Positive for Biotype Thailandensis – soil isolates..? Avirulent as most clinical isolates are negative
  24. 24. Agents continued… - Virulence markers
  25. 25. Pathogenicity / virulence markers BCC B. Pseudomallei Cellular structures Transmissibility factors viz, cable like pilus & BCESM (Path island) Drug resistance: efflux pumps Biofilm formation Co-colonisation with P.aeruginosa Capsular polysaccharide, LPS, O-PS : PUTATTIVE virulence factors Flagella: for invasion ? Not proved though Genetic BCESM – part of novel path island important role in colonisation TTSS geneclusters for bacterial effector molecules that help escape into cytoplasm and intracellular survival .. Toxic products Endotoxin: LPS Polymixin resistance due to presence of amino-4-deoxy-L-arabinose: in inner core region ..prevents drug binding Two heat labile exo?-toxins: proteolytic Extracellular enzymes and siderophores Ornibactin, pyochelin, salicylic acid, cepabactin Ptrotease, lecithinase, lipase; Hydroxamate siderophore, malleobactin= siderophores sequester Fe fron transferrin & lactoferrin
  26. 26. Typing • Pseudomallei – Phages, chromosomal DNA analysis • BCC – Bacteriocin, phage, Chromosomal DNA analysis, and plasmid
  27. 27. Melioidosis – Pathology & Pathogenesis • Poorly understood • Pyogenic organism – Histopath: acute & or chronic..mixed • Intracellular globi of Gram Neg Bacilli combine with giant cells in a background of acute necrotising inflammation • Outcome depends on – Host’s immune system – Virulence of the strain – Size and route of initial inoculum • Host defence – 50-70% underlying predisposition; probably altered host CMI impact manifestations • Host response – Ab to O-PSII higher in survivors
  28. 28. Immunopathogenesis Data from in vitro and animal studies intracellular- invasion, survival and replication in both phago & Nonphagocytic cells Escaping endocytic vesicles and Breakout into cytoplasm & replicate OR infect other cells through actin based membrane protrusions which help in spreading infection N Engl J Med 2012;367:1035-44
  29. 29. Environment
  30. 30. BCC & gladioli in some cases B. Pseudomallei B. mallei Source/ Habitat/ Ecology Mostly western data. Ubiquitous. Not part of normal human flora, but may colonise CF pts Asymptomatic Carriage in CF pts, 5% UK centre; From Pts’ domestic/natural environment ie from agricultural soil is also reported; Hospital-water supplies, pharmacies, nebulised medicines eg albuterol, antiseptic/disinfectant solutions, tubing for irrigation, monitoring lines, sinks, Air samples in treatment rooms But proved to be a environmental saprophyte – in Damp climate, terrain of low lying plains- – soil(rice paddy), water Endemic regions: limited to SE Asia, North Australia, South & Central America Does not form spores, Thailand: 68-78% of rice fields isolation NOTE:B. thailandensis – coexists, among soil isolates not clinical - Biotype L-Arabinose positive strains and ribotype II ?avirulent. Noncultivable intracellular protozoa/ soil forms. Close contact with infected animal/ person; delicate organism than pseudomallei = poor survival in environment therefore.. Obligate parasite of horses, mules, donkeys isolation exceedingly rare; few foci in Asia, Africa and the middle east Transmission Respiratory droplet infection/ wound contamination/ contact/ procedures Strict following of std precautions necessary. Identified in 6-25%; POORLY understood. Inoculation/ contamination of open wounds/ aerosols in post monsoon/? waterborne outbreaks; person to person or animal to person rarely reported; though lab aquired cases are seen warrants Level 3 Safety Human glanders by contamination of wounds/ abrasion/mucus membrane. Inhalational – lab worker Requires isolation of patients Susceptibility Can contaminate chlorhexidine and cetrimide. Resistant to polymixin, ticarcillin, azlocillin, imipenem. Variable-quinolones, tetracycline. Sensitive to cotrimoxazole & chloramphenicol Synergy combinations – ? Not rec Sodium hypochlorite at 500 ppm chlorine for 5 minutes or 5% phenol for 10-15 minutes Soil decontamination using Hypochlorite - french outbreak 1970 Delicate, sensitive to aminoglycosides.
  31. 31. Epidemiology - Host Pseudomallei - Melioidosis
  32. 32. DATA on Melioidosis – from Highly Endemic regions • Regular contact with soil and water, as in rice farmers – mainly occupational =81% rice farmers and their children • Incubation period: 2days to 26years • Annual incidence rate vary – Australia &Thailand - up to 50 cases per 100,000 people • All age groups – Peak from 40-60years – Male :Female = 3:2 • Seasonal – 75% cases in rainy season, mainly for acute cases • Underlying risk factors: – DM (100 FOLD)
  33. 33. B. pseudomallei N Engl J Med 2012;367:1035-44
  34. 34. Indian literature - Pseudomallei • 1991 first reported from Bombay – Raghavan KR, Shenoi RP, Zaer F, Aiyer R, Ramamoorthy P, Mehta MN. Melioidosis in India. Indian Pediatr 1991;28:184-8 • Later onwards several case reports/series from CMC/JIPMER/MANGLORE/St Johns
  35. 35. 2003 - AIMS
  36. 36. 2008 - From SJMC
  37. 37. Emergence of Burkholderia pseudomallei and pandrug-resistant non-fermenters from southern Karnataka, India C. Mukhopadhyay et al Trans R Soc Trop Med Hyg (2008) Summary points • ………..outcome of 25 patients with melioidosis and 46 patients with MDR non-fermenters (Pseudomonas aeruginosa and Acinetobacter spp.) infection were documented during the period 2005 2007. • Skin and soft-tissue involvement (16%), liver abscess (16%) and bone and joint involvement (16%) were the most common presentations of melioidosis in diabetic patients. The presence of septicaemia (44%) and major organ failure (48%) resulted in death. Relapse was seen in patients with inappropriate treatment. … • More awareness among clinicians and laboratory staff, and environmental investigations of soil are required for accurate diagnosis and prompt treatment of melioidosis.
  38. 38. Neonatal melioidosis: A case report from India..JIPMER • Indian Journal of Medical Microbiology, Vol. 27, No. 3, July-September, 2009, pp. 260-263 • Melioidosis, caused by Burkholderia pseudomallei , is an infectious disease of major public health importance in Southeast Asia and Australia. .. • A pre-term female baby developed respiratory distress soon after birth. The child was febrile, had tachypnea, grunting, normal heart rate with a low pulse volume and poor peripheral perfusion. Chest X-ray revealed right-sided bronchopneumonia. B. pseudomallei was isolated from the blood culture of the neonate collected aseptically. The neonate was successfully treated with meropenem.
  39. 39. Last year – 2012 Western coast in India – endemic
  40. 40. KMC Manipal study As it is one study with highest no patient population = 95
  41. 41. Indian data Emerging clinico-epidemiological rends in melioidosis: analysis of 95 cases from western coastal India Department of Microbiology, Kasturba Medical College, Manipal University, Light House Hill Road, Mangalore K. Vidyalakshmi et al.
  42. 42. RISK FACTORS
  43. 43. Epidemiology – Host - BCC
  44. 44. BCC – Cystic fibrosis and HAI • Hospital outbreaks • Candian outbreak – ET12 strain with cable like pilus • 5% colonisation – mainly adult population low rates overall • But spectrum of disease • Asymptomatic carriage to rapid decline of lung function • Higher mortality among colonised • Lung transplants – higher mortality • CROSS INFECTIONS – With infection control measures - transmission can be brought under control between CF patients eg in treatment rooms
  45. 45. CDC study – on BCC literature Proportion of sequence types (STs) within each Burkholderia cepacia complex (Bcc) species from clinical, environmental, or both sources
  46. 46. Clinical features
  47. 47. Melioidosis • Remarkable imitator – Staph/MTB Spectrum • Mild & subclinical infections - seroepidemiology • Latent infections ie why its called as… • Clinical disease - small proportion of cases – Septicemic – prothrombotic state, multiorgan failure, multiple foci in lung/liver and most pathognomonic spleen later neurologic » Peripheral motor weakness, Brainstem encephelitis, Aseptic meningitis, Respiratory failure – Localised melioidosis » Lung/Acute suppurative parotitis in children
  48. 48. Details @
  49. 49. Outcome and follow up • Mortality 40-50%in thailand – Australia 19% Relapse? 1-26% = Chronic morbidity with both disease & underlying conditions = longterm follow up needed = clues for relapse: CRP Important as emergence of resistance during treatment period is known
  50. 50. Meliodosis – India KMC Manipal study
  51. 51. Glanders Clinical features
  52. 52. Burkholderia mallei • Glanders – – primarily affects horses, mules, and donkeys. – can infect humans • Cause of concern – likely candidate for biological warfare and bioterrorism – World War I, German forces reportedly spread glanders to debilitate enemy cavalries. • Transmission – enter the body through cuts in the skin or the membranes of the eyes and nose; also can be inhaled, and as an aerosol glanders would be a deadly weapon • Incubation period before symptoms - 1-14 days
  53. 53. Burkholderia mallei • Symptoms: • fever and headaches muscle aches, muscle tightness, chest pain, • Local lesions at entry—through the skin, eyes, nose, or respiratory tract – pustular lesions that develop 1-5 days after bacteria enter breaks in the skin, local swollen lymph nodes, tearing of the eyes, light sensitivity increased mucus in the eyes, nose, and pneumonia
  54. 54. DIAGNOSIS
  55. 55. Meliodosis – Diagnosis • Clinical features, patient from endemic area or with h/o travel • Radiological – splenic/hepatic abscess swiss cheese • Microbiological – Gold Standard – Culture • Confirmatory even with single colony – Confirmation by latex agglutination • Serological - IHA • Molecular – Real-Time PCR Assay Targeting the Type III Secretion System of Burkholderia pseudomallei
  56. 56. Perspective Piece - Clinical Definitions of Melioidosis • provide case definitions of melioidosis (Burkholderia pseudomallei infection) and describe the evidence on which these are based. There are two definitions that reflect the purpose for which they may be used Am. J. Trop. Med. Hyg., 88(3), 2013, pp. 411–413
  57. 57. Culture confirmation
  58. 58. IHA - Indirect haemagglutination
  59. 59. Monoclonal antibody specific to B. pseudomallei (Mab-IFA) Am. J. Trop. Med. Hyg., 89(1), 2013, pp. 165–168 • prospective cohort of 951 consecutive patients with suspected melioidosis against culture as the gold standard • 48.4% for sensitivity, • and 99.8% for specificity
  60. 60. Management
  61. 61. Management & Prevention • Improved diagnostics and training of health care workers • Intensive treatment and mantainace with follow ups – Aiming for cure of meliodosis • Among Laboratory workers – Awareness – Using biosafety cabinets as recommended to be used; standard precautions – Prophylaxis in exposed individuals • Vaccine research • Soil testing, awareness among patient population
  62. 62. Treatment
  63. 63. Prevention & Vaccine • Potentially preventable, but no evidence for development of guidelines for prevention • Recommended for high risk: – Stay indoors during monsoon /wind/rain • Aerosolisation avoid • No evidence to support human-to-human transmission through respiratory route • No vaccine available to date – Research • Using live attennuated, subunit, plasmid based, and killed whole – cell candidates
  64. 64. Preventive measures: Thailand • Thailand Laos Melioidosis Network Meeting II – 17 September 2012, meet twice a year • Update from 2nd TLMNM - Melioidosis
  65. 65. Thailand – preventive measures 1. Surveillance & Public awareness
  66. 66. Thailand – preventive measure 2. improved diagnosis and prevention
  67. 67. Manipal – Dr C. Mukhyopadhyaya in collaboration with Dr Sharon Peacock
  68. 68. Mahidol university, Thailand
  69. 69. Major References • Topley Wilson • Mandel • CMR – Melioidosis • NEJM review2012
  70. 70. Acknowledgement • Dr H. Srinivasa • Dr Sharon Peacock • Dr David Dance
  71. 71. Thank you

×